<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="openVirus\examples\priya950\4-part\PMC7173238\results\search\disease\results.xml">
  <result pre="multi-target activity against viral infections of great medical importance (e.g.," exact="herpes simplex" post="virus (HSV), varicella zoster virus (VZV), human immunodeficiency virus"/>
  <result pre="virus (HSV), varicella zoster virus (VZV), human immunodeficiency virus (HIV)," exact="hepatitis" post="B virus (HBV) and hepatitis C virus (HCV)) and/or"/>
  <result pre="(VZV), human immunodeficiency virus (HIV), hepatitis B virus (HBV) and" exact="hepatitis" post="C virus (HCV)) and/or that are known antineoplastic agents"/>
  <result pre="Experimental development Acyclovir Acyclic guanosine analogue HSV, VZV (1982) Breast" exact="cancer" post="(Shaimerdenova et al., 2017)EBV (Pagano et al., 2018) Azacitidine"/>
  <result pre="al., 2018) Gemcitabine Cytidine analogue Various carcinomas (1995): non-small cell" exact="lung cancer," post="pancreatic cancer, bladder cancer breast cancer ovarian cancer HIV-1"/>
  <result pre="Gemcitabine Cytidine analogue Various carcinomas (1995): non-small cell lung cancer," exact="pancreatic cancer," post="bladder cancer breast cancer ovarian cancer HIV-1 (Rawson et"/>
  <result pre="analogue Various carcinomas (1995): non-small cell lung cancer, pancreatic cancer," exact="bladder cancer" post="breast cancer ovarian cancer HIV-1 (Rawson et al. (2013);"/>
  <result pre="Various carcinomas (1995): non-small cell lung cancer, pancreatic cancer, bladder" exact="cancer" post="breast cancer ovarian cancer HIV-1 (Rawson et al. (2013);"/>
  <result pre="carcinomas (1995): non-small cell lung cancer, pancreatic cancer, bladder cancer" exact="breast cancer" post="ovarian cancer HIV-1 (Rawson et al. (2013); Clouser et"/>
  <result pre="(1995): non-small cell lung cancer, pancreatic cancer, bladder cancer breast" exact="cancer" post="ovarian cancer HIV-1 (Rawson et al. (2013); Clouser et"/>
  <result pre="non-small cell lung cancer, pancreatic cancer, bladder cancer breast cancer" exact="ovarian cancer" post="HIV-1 (Rawson et al. (2013); Clouser et al. (2010);"/>
  <result pre="cell lung cancer, pancreatic cancer, bladder cancer breast cancer ovarian" exact="cancer" post="HIV-1 (Rawson et al. (2013); Clouser et al. (2010);"/>
  <result pre="in combination with inarigivir) Trifluridine Thymidine analogue HSV (1980) Metastatic" exact="colorectal cancer" post="(2015) in combination with tipiracil Mycoplasma pneumonia (Sun and"/>
  <result pre="combination with inarigivir) Trifluridine Thymidine analogue HSV (1980) Metastatic colorectal" exact="cancer" post="(2015) in combination with tipiracil Mycoplasma pneumonia (Sun and"/>
  <result pre="(1980) Metastatic colorectal cancer (2015) in combination with tipiracil Mycoplasma" exact="pneumonia" post="(Sun and Wang, 2013) Valaciclovir Acyclic guanosine analogue HSV,"/>
  <result pre="humans worldwide (Leoni et al., 2018). According to the WHO," exact="viral hepatitis" post="caused 1.34 million deaths in 2015, a number that"/>
  <result pre="worldwide (Leoni et al., 2018). According to the WHO, viral" exact="hepatitis" post="caused 1.34 million deaths in 2015, a number that"/>
  <result pre="is comparable to the number of annual deaths caused by" exact="tuberculosis" post="and that is even higher than those attributed to"/>
  <result pre="is even higher than those attributed to HIV. A global" exact="hepatitis" post="report concluded that mortality from HIV, tuberculosis, and malaria"/>
  <result pre="global hepatitis report concluded that mortality from HIV, tuberculosis, and" exact="malaria" post="is now declining, while mortality from viral hepatitis has"/>
  <result pre="HIV, tuberculosis, and malaria is now declining, while mortality from" exact="viral hepatitis" post="has been increasing over time (World Health Organization, 2017)."/>
  <result pre="tuberculosis, and malaria is now declining, while mortality from viral" exact="hepatitis" post="has been increasing over time (World Health Organization, 2017)."/>
  <result pre="These individuals are at risk of developing severe complications, including" exact="cirrhosis" post="and hepatocellular carcinoma. In 2015, hepatitis B resulted in"/>
  <result pre="are at risk of developing severe complications, including cirrhosis and" exact="hepatocellular carcinoma." post="In 2015, hepatitis B resulted in 887,000 deaths, mostly"/>
  <result pre="developing severe complications, including cirrhosis and hepatocellular carcinoma. In 2015," exact="hepatitis" post="B resulted in 887,000 deaths, mostly due to complications."/>
  <result pre="and mortality among those living with HIV and coinfected with" exact="viral hepatitis." post="People with these conditions should be prioritized for diagnosis"/>
  <result pre="HBV infections. Telbivudine (L-thymidine) is used in the treatment of" exact="hepatitis" post="B infection. Clinical trials have shown that this drug"/>
  <result pre="endothelial-protective effects on B19V-infected endothelial cells and improves the chronic" exact="myocarditis" post="associated with B19V transcriptional activity (Van Linthout et al.,"/>
  <result pre="approved by the FDA in 2013 for use against chronic" exact="hepatitis" post="C infection. Sofosbuvir was the first drug that demonstrated"/>
  <result pre="(NCT03312023). It has been observed that patients who had both" exact="hepatitis" post="B and hepatitis C and who were treated for"/>
  <result pre="been observed that patients who had both hepatitis B and" exact="hepatitis" post="C and who were treated for hepatitis C for"/>
  <result pre="hepatitis B and hepatitis C and who were treated for" exact="hepatitis" post="C for 12 weeks with a combination of ledipasvir/sofosbuvir"/>
  <result pre="for 12 weeks with a combination of ledipasvir/sofosbuvir had decreased" exact="hepatitis" post="B surface antigen levels. This finding was the basis"/>
  <result pre="a similar decrease could be observed in mono-infected individuals with" exact="hepatitis" post="B. Sofosbuvir was also recently shown to protect against"/>
  <result pre="flaviviruses, such as dengue virus (DENV) (Xu et al., 2017)," exact="yellow fever" post="virus (YFV) (De Freitas et al., 2019), and chikungunya"/>
  <result pre="yellow fever virus (YFV) (De Freitas et al., 2019), and" exact="chikungunya" post="virus (CHIKV) (Ferreira et al., 2019). 3 Multi-target nucleos(t)ide-based"/>
  <result pre="in DMSO is available for the treatment of herpes labialis," exact="herpes genitalis" post="and herpes zoster (Aoki, 2015). Fig. 4 Nucleoside-based marketed"/>
  <result pre="available for the treatment of herpes labialis, herpes genitalis and" exact="herpes zoster" post="(Aoki, 2015). Fig. 4 Nucleoside-based marketed drugs against various"/>
  <result pre="brivudine, famciclovir and valaciclovir treatment in immunocompetent adult patients with" exact="herpes zoster" post="indicate that brivudine may be the first choice in"/>
  <result pre="brivudine may be the first choice in cases of severe" exact="herpes zoster" post="because of its ability to promptly control pain and"/>
  <result pre="been evaluated for their cytotoxic activity against a panel of" exact="cancer" post="cell lines. Compared to parent nucleoside, such as idoxuridine"/>
  <result pre="monophosphate, it inhibits thymidylate synthetase, which is elevated in different" exact="cancer" post="cell lines. After further phosphorylation, the corresponding triphosphate competitively"/>
  <result pre="European Union for the treatment of adult patients with metastatic" exact="colorectal cancer" post="who were previously subjected to chemotherapy involving fluoropyrimidine, oxaliplatin"/>
  <result pre="Union for the treatment of adult patients with metastatic colorectal" exact="cancer" post="who were previously subjected to chemotherapy involving fluoropyrimidine, oxaliplatin"/>
  <result pre="efficacy of trifluridine-tipiracil during the treatment of patients with metastatic" exact="colorectal cancer" post="(NCT03306394). Trifluridine was also tested as an antibacterial agent."/>
  <result pre="of trifluridine-tipiracil during the treatment of patients with metastatic colorectal" exact="cancer" post="(NCT03306394). Trifluridine was also tested as an antibacterial agent."/>
  <result pre="2017, studies conducted to determine the effect of acyclovir on" exact="breast cancer" post="MCF-7 cells were described (Shaimerdenova et al., 2017). The obtained"/>
  <result pre="studies conducted to determine the effect of acyclovir on breast" exact="cancer" post="MCF-7 cells were described (Shaimerdenova et al., 2017). The obtained"/>
  <result pre="The obtained results demonstrate the suppressive effect of acyclovir on" exact="breast cancer" post="cells. Acyclovir treatment decreases the proliferation rate as well"/>
  <result pre="obtained results demonstrate the suppressive effect of acyclovir on breast" exact="cancer" post="cells. Acyclovir treatment decreases the proliferation rate as well"/>
  <result pre="inhibits the colony formation ability and cell invasion capacity of" exact="cancer" post="cells. These results demonstrate the possibility of partial suppression"/>
  <result pre="of cancer cells. These results demonstrate the possibility of partial" exact="suppression" post="of cancer cell proliferation using this antiviral agent. However,"/>
  <result pre="cells. These results demonstrate the possibility of partial suppression of" exact="cancer" post="cell proliferation using this antiviral agent. However, further research"/>
  <result pre="would be a cytotoxic agent when properly delivered to the" exact="cancer" post="cells. To facilitate the targeted delivery of phosphorylated acyclovir"/>
  <result pre="penciclovir probably distorts the DNA conformation and then induces the" exact="suppression" post="of further DNA elongation (Piret and Boivin, 2011). Penciclovir"/>
  <result pre="EBV-infectious mononucleosis (NCT00575185) as well as for the treatment of" exact="herpes zoster" post="(NCT00831103). Cyclopropavir (MBX-400) is another extensively investigated compound. It"/>
  <result pre="a phase 2 clinical trial in comparison with valaciclovir for" exact="herpes zoster" post="(NCT00900783) and in a phase 3 clinical trial in"/>
  <result pre="including leukaemias, lymphomas, and pancreatic, breast, bladder, ovarian, colon or" exact="kidney cancer." post="By mimicking the physiological role of their natural counterparts,"/>
  <result pre="floxuridine in 1970), which have had important roles in several" exact="cancer" post="treatments (Parker, 2009). Some of the cytotoxic nucleoside analogues"/>
  <result pre="bacteria were lower than those used for the treatment of" exact="cancer" post="patients, which can reduce the problem of toxicity (Jordheim"/>
  <result pre="for the treatment of locally advanced or metastatic non-small cell" exact="lung cancer," post="and Gemzar in combination with paclitaxel was approved as"/>
  <result pre="was approved as the first-line therapy for women battling metastatic" exact="breast cancer." post="Gemzar demonstrates dose-dependent synergistic activity with cisplatin. In the"/>
  <result pre="dose-dependent synergistic activity with cisplatin. In the treatment of advanced" exact="ovarian cancer" post="(at least 6 months after completion of platinum-based therapy),"/>
  <result pre="synergistic activity with cisplatin. In the treatment of advanced ovarian" exact="cancer" post="(at least 6 months after completion of platinum-based therapy),"/>
  <result pre="study showed that co-treatment with gemcitabine and zidovudine re-sensitized gemcitabine-resistant" exact="pancreatic cancer" post="by inhibiting the key signalling pathway, Akt-GSK3β-Snail1, in the"/>
  <result pre="showed that co-treatment with gemcitabine and zidovudine re-sensitized gemcitabine-resistant pancreatic" exact="cancer" post="by inhibiting the key signalling pathway, Akt-GSK3β-Snail1, in the"/>
  <result pre="brivudine with gemcitabine or cisplatin enhanced their efficacy as a" exact="pancreatic cancer" post="therapy (Heinrich et al., 2011). Recently (2018), the FDA"/>
  <result pre="with gemcitabine or cisplatin enhanced their efficacy as a pancreatic" exact="cancer" post="therapy (Heinrich et al., 2011). Recently (2018), the FDA"/>
  <result pre="FDA in 2004 for the treatment of all subtypes of" exact="myelodysplastic syndrome" post="(MDS). To date, azacytidine has also been approved for"/>
  <result pre="FDA in 2006 for the treatment of multiple types of" exact="myelodysplastic syndrome." post="It promotes cytotoxic DNA hypomethylation and cell death in"/>
  <result pre="et al., 2017). Additionally, it was shown that in muscle-invasive" exact="bladder cancer" post="cells, decitabine treatment (at low non-cytotoxic doses) restored NOTCH1"/>
  <result pre="al., 2017). Additionally, it was shown that in muscle-invasive bladder" exact="cancer" post="cells, decitabine treatment (at low non-cytotoxic doses) restored NOTCH1"/>
  <result pre="and decitabine at concentrations much lower than those used in" exact="cancer" post="treatment synergistically lowered HIV-1 infectivity by 73% and significantly"/>
  <result pre="inhibitor from an HSP90 inhibitor as a selective inhibitor of" exact="hepatitis" post="C virusPLoS One72012e3028610.1371/journal.pone.0030286 BöslK.IanevskiA.ThanT.T.AndersenP.I.KuivanenS.TepporM.ZusinaiteE.DumpisU.VitkauskieneA.CoxR.J.Kallio-KokkoH.BergqvistA.TensonT.OksenychV.BjøråsM.AnthonsenM.W.ShumD.KaarbøM.VapalahtiO.WindischM.P.Superti-FurgaG.SnijderB.KainovD.KandasamyR.K.Critical nodes of virus-host interaction revealed"/>
  <result pre="vivoPLoS Neglected Trop. Dis.132019e000707210.1371/journal.pntd.0007072 DenisovaO.V.KakkolaL.FengL.StenmanJ.NagarajA.LampeJ.YadavB.AittokallioT.KaukinenP.AholaT.KuivanenS.VapalahtiO.KanteleA.TynellJ.JulkunenI.Kallio-KokkoH.PaavilainenH.HukkanenV.ElliottR.M.De BrabanderJ.K.SaelensX.KainovD.E.Obatoclax, saliphenylhalamide, and gemcitabine inhibit" exact="influenza" post="A virus infectionJ. Biol. Chem.2872012353243533210.1074/jbc.M112.39214222910914 DiamantopoulosP.T.MichaelM.BenopoulouO.BazanisE.TzeletasG.MeletisJ.VayopoulosG.ViniouN.A.Antiretroviral activity of 5-azacytidine"/>
  <result pre="DiamantopoulosP.T.MichaelM.BenopoulouO.BazanisE.TzeletasG.MeletisJ.VayopoulosG.ViniouN.A.Antiretroviral activity of 5-azacytidine during treatment of a HTLV-1 positive" exact="myelodysplastic syndrome" post="with autoimmune manifestationsVirol. J.92012110.1186/1743-422X-9-122214262 DyallJ.ColemanC.M.HartB.J.VenkataramanT.HolbrookM.R.KindrachukJ.JohnsonR.F.OlingerG.G.JahrlingP.B.LaidlawM.JohansenL.M.Lear-RooneyC.M.GlassP.J.HensleyL.E.FriemanM.B.Repurposing of clinically developed drugs"/>
  <result pre="Faria NetoH.C.BoechatN.RehenS.K.BrüningK.BozzaF.A.BozzaP.T.SouzaT.M.L.Beyond members of the Flaviviridae family, sofosbuvir also inhibits" exact="chikungunya" post="virus replicationAntimicrob. Agents Chemother.63201910.1128/AAC.01389-18e01389-18 FlorescuD.F.PergamS.A.NeelyM.N.QiuF.JohnstonC.WayS.S.SandeJ.LewinsohnD.A.Guzman-CottrillJ.A.GrahamM.L.PapanicolaouG.KurtzbergJ.RigdonJ.PainterW.Mommeja-MarinH.LanierR.AndersonM.van der HorstC.Safety and efficacy"/>
  <result pre="shock protein HSP27 (HSPB1) and enhances survival in animals and" exact="pancreatic cancer" post="patientsJ. Cancer Res. Clin. Oncol.13720111349136110.1007/s00432-011-1005-121833720 HertelL.W.BoderG.B.KroinJ.S.RinzelS.M.PooreG. aToddG.C.GrindeyG.B.Evaluation of the"/>
  <result pre="protein HSP27 (HSPB1) and enhances survival in animals and pancreatic" exact="cancer" post="patientsJ. Cancer Res. Clin. Oncol.13720111349136110.1007/s00432-011-1005-121833720 HertelL.W.BoderG.B.KroinJ.S.RinzelS.M.PooreG. aToddG.C.GrindeyG.B.Evaluation of the"/>
  <result pre="JordheimL.P.DurantelD.ZoulimF.DumontetC.Advances in the development of nucleoside and nucleotide analogues for" exact="cancer" post="and viral diseasesNat. Rev. Drug Discov.12201344746410.1038/nrd401023722347 JulanderJ.G.SiddharthanV.EvansJ.TaylorR.TolbertK.ApuliC.StewartJ.CollinsP.GebreM.NeilsonS.Van WettereA.LeeY.M.SheridanW.P.MorreyJ.D.BabuY.S.Efficacy of"/>
  <result pre="differentially affect cellular signaling, transcription and metabolismAntivir. Res.139201711712810.1016/j.antiviral.2016.12.02228049006 LahmerT.HoffmannD.HeemannU.KüchleC.FrankH.Epstein-Barr virus" exact="encephalitis" post="after kidney transplantation and successful treatment with brivudineTranspl. Int.232010e24e2510.1111/j.1432-2277.2009.01045.x20070626"/>
  <result pre="and subtype profiling of PSI-7977 as a nucleotide inhibitor of" exact="hepatitis" post="C virusAntimicrob. Agents Chemother.5620123359336810.1128/aac.00054-1222430955 LaskinO.L.Acyclovir: pharmacology and clinical experienceArch."/>
  <result pre="virusAntimicrob. Agents Chemother.27198597197310.1128/AAC.27.6.9712992367 LittlerE.ZhouX.-X.Deoxyribonucleic acid viruses: antivirals for herpesviruses and" exact="hepatitis" post="B virusCompr. Med. Chem. II200729532710.1016/b0-08-045044-x/00212-1 LiuL.Z.SunJ.HouJ.ChanH.L.Y.Improvements in the management"/>
  <result pre="virusCompr. Med. Chem. II200729532710.1016/b0-08-045044-x/00212-1 LiuL.Z.SunJ.HouJ.ChanH.L.Y.Improvements in the management of chronic" exact="hepatitis" post="B virus infectionExpert Rev. Gastroenterol.1220181153116610.1080/17474124.2018.1530986 LookerK.J.MagaretA.S.MayM.T.TurnerK.M.E.VickermanP.GottliebS.L.NewmanL.M.Global and regional estimates"/>
  <result pre="Rev. Gastroenterol.1220181153116610.1080/17474124.2018.1530986 LookerK.J.MagaretA.S.MayM.T.TurnerK.M.E.VickermanP.GottliebS.L.NewmanL.M.Global and regional estimates of prevalent and incident" exact="herpes simplex" post="virus type 1 infections in 2012PLoS One10201511710.1371/journal.pone.0140765 LuberA.D.FlahertyJ.F.Famciclovir for"/>
  <result pre="of varicella zoster virusJ. Antimicrob. Chemother.6020071316133010.1093/jac/dkm37617956908 Menéndez-AriasL.�?lvarezM.PachecoB.Nucleoside/nucleotide analog inhibitors of" exact="hepatitis" post="B virus polymerase: mechanism of action and resistanceCurr. Opin."/>
  <result pre="liquid chromatographyJ. Virol. Methods161200922323010.1016/j.jviromet.2009.06.01619559728 NambaT.KodamaR.MoritomoS.HoshinoT.MizushimaT.Zidovudine, an anti-viral drug, resensitizes gemcitabine-resistant" exact="pancreatic cancer" post="cells to gemcitabine by inhibition of the Akt-GSK3β-Snail pathwayCell"/>
  <result pre="chromatographyJ. Virol. Methods161200922323010.1016/j.jviromet.2009.06.01619559728 NambaT.KodamaR.MoritomoS.HoshinoT.MizushimaT.Zidovudine, an anti-viral drug, resensitizes gemcitabine-resistant pancreatic" exact="cancer" post="cells to gemcitabine by inhibition of the Akt-GSK3β-Snail pathwayCell"/>
  <result pre="in the treatment of cancerChem. Rev.10920092880289310.1021/cr900028pEnzymology19476376 PaulyM.D.LauringA.S.Effective lethal mutagenesis of" exact="influenza" post="virus by three nucleoside analogsJ. Virol.8920153584359710.1128/jvi.03483-1425589650 PiretJ.BoivinG.Resistance of herpes"/>
  <result pre="of influenza virus by three nucleoside analogsJ. Virol.8920153584359710.1128/jvi.03483-1425589650 PiretJ.BoivinG.Resistance of" exact="herpes simplex" post="viruses to nucleoside analogues: mechanisms, prevalence, and managementAntimicrob. Agents"/>
  <result pre="of thymidineBBA - Biochim. Biophys. Acta32195929529610.1016/0006-3002(59)90597-913628760 QuenelleD.C.LampertB.CollinsD.J.RiceT.L.PainterG.R.KernE.R.Efficacy of CMX001 against" exact="herpes simplex" post="virus infections in mice and correlations with drug distribution"/>
  <result pre="reductaseBioorg. Med. Chem.2420162410242210.1016/j.bmc.2016.03.05227117260 RehermannB.BertolettiA.Immunological aspects of antiviral therapy of chronic" exact="hepatitis" post="B virus and hepatitis C virus infectionsHepatology61201571272110.1002/hep.2732325048716 SagnelliE.SagnelliC.MaceraM.PisaturoM.CoppolaN.An update"/>
  <result pre="aspects of antiviral therapy of chronic hepatitis B virus and" exact="hepatitis" post="C virus infectionsHepatology61201571272110.1002/hep.2732325048716 SagnelliE.SagnelliC.MaceraM.PisaturoM.CoppolaN.An update on the treatment options"/>
  <result pre="the nucleoside scaffoldAntivir. Res.1542018668610.1016/j.antiviral.2018.04.00429649496 ShaimerdenovaM.KarapinaO.MektepbayevaD.AlibekK.AkilbekovaD.The effects of antiviral treatment on" exact="breast cancer" post="cell lineInfect. Agents Cancer12201711010.1186/s13027-017-0128-728053656 ShinH.J.KimC.ChoS.Gemcitabine and nucleos(t)ide synthesis inhibitors"/>
  <result pre="nucleoside scaffoldAntivir. Res.1542018668610.1016/j.antiviral.2018.04.00429649496 ShaimerdenovaM.KarapinaO.MektepbayevaD.AlibekK.AkilbekovaD.The effects of antiviral treatment on breast" exact="cancer" post="cell lineInfect. Agents Cancer12201711010.1186/s13027-017-0128-728053656 ShinH.J.KimC.ChoS.Gemcitabine and nucleos(t)ide synthesis inhibitors"/>
  <result pre="luoro-2′-β- C -methyluridine Nucleotide Prodrug (PSI-7977) for the treatment of" exact="hepatitis" post="C virusJ. Med. Chem.5320107202721810.1021/jm100863x20845908 SongJ.H.KimS.R.HeoE.Y.LeeJ.Y.KimD. eunChoS.ChangS.Y.YoonB. IlSeongJ.KoH.J.Antiviral activity of"/>
  <result pre="analogsBMC Microbiol.13201318410.1186/1471-2180-13-18423919755 ThackrayA.M.FieldH.J.Famciclovir and valaciclovir differ in the prevention of" exact="herpes simplex" post="virus type 1 latency in mice: a quantitative studyAntimicrob."/>
  <result pre="placebo- controlled trialAnn. Intern. Med.1231995899610.7326/0003-4819-123-2-199507150-000027778840 Van LinthoutS.ElsanhouryA.KleinO.SosnowskiM.MitevaK.LassnerD.Abou-El-EneinM.PieskeB.KühlU.TschöpeC.Telbivudine in chronic lymphocytic" exact="myocarditis" post="and human parvovirus B19 transcriptional activityESC Hear. Fail.5201881882910.1002/ehf2.12341 VatnerS.F.ParkM.YanL.LeeG.J.LaiL.IwatsuboK.IshikawaY.PessinJ.VatnerD.E.Adenylyl"/>
 </snippets>
</snippetsTree>
